1/19
Looks like no tags are added yet.
Investigational New Drug (IND) application
After enough preclinical development, an IND application can be submitted to FDA
Allows sponsor to propose beginning clinical trials in humans
FDA reviews submission before proposed clinical study proceeds
The IND includes info on…
Pharmacology and toxicology
Manufacturing and formulation
Proposed clinical trial protocols
Clinical investigator information
Clinical trials
- Studies conducted on human participants according to an approved clinical trial protocol
- Evaluate safety, dose, efficacy
- Progress thru Phases I to III
Double blind studies
- Participants don't know their treatment assignment
- Investigators involved in treatment/assessment don't know the assignment
Components of double blind studies
- Compare treatment groups: investigational drug vs. placebo/active treatment
- Placebo effect: must be scien+ethically appropriate
- Helps reduce bias
Nuremberg code (1947)
- Developed following the Nuremberg Doctors' trials after WW2
- Responded to unethical human experimentation
- Established fundamental principles for ethical research involving humans
- Foundation of modern research ethics
Key principles of Nuremberg code
- Voluntary participiation
- Informed consent
- Risks justified by potential benefits
Modern clinical research ethics
- Declaration of Helsinki
- Good clinical practice (GCP)
- Ethics committee
- Informed consent
- Applicable national reg's
Regulatory oversight of drug development
- Regulatory agencies oversee drug development & clinical trials
- Help ensure safety, efficacy & quality standards
- Review reg. submissions & trial data
- Major authorities: FDA, Health Canada
Phase I clinical trials
- 20-100 (often healthy) participants
- Focus on safety, dose, pharmacokinetics (PK)
- 70% proceed to Phase II
- Duration: months to 1 yr
Phase II clinical trials
- 100's (diseased/condition) patients
- Focus on efficacy, dose, safety
- 30% proceed to Phase III
- Duration months to 2 yrs
Phase III clinical trials
- 300-3000 patients (in target patient popu)
- Focus on confirming efficacy, safety, identifying less common adverse effects
- 25-30% proceed to regulatory submission
- Duration: 1-4 yrs
New drug application (NDA)
- Formal application to FDA requesting approval to market new drug
- Includes pre+clinical data, safety, labeling
- FDA review timeline includes priority & standard review
- Modern submission r electronic
Post-approval (Phase IV)
- Drug enters wider clinical use
- Postmarketing safety surveillance
- Continued development may investigate new indications
- May evaluate long-term safety, drug int's
New safety info may lead to... (Phase IV)
- Labeling changes
- Extra studies/restrictions
Orphan drugs
- Drugs developed for rare diseases or conditions
- Development challenges: small patient popu's, hard to recruit ppl
- US incentives: tax credits, waiver of some FDA fees
Theory of teratogenicity for thalidomide
Based on animal experiments in 1970’s
D was sold as a racemate: S enantiomer was teratogenic → vasoconstrictor
Difficult to reprod the exp
Enantiomer effect requires i.p. dosing (injection)
Racemization of the D

FDA oversight of drugs
Sponsors generate & submit data
FDA reviews evidence & conducts inspections
After approval, continued safety monitoring, comapanies report adverse-event info
Benefits of industry regulation
Ensure safe, effective & consistent quality products
Provides consumer protection
Challenges of industry regulation
Adds time & cost to D development
Regulatory requirements can affect speed of access
Requires extensive documentation & oversight